These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 16955082)

  • 1. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
    Bochner BH
    Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.
    Böhle A; Bock PR
    Urology; 2004 Apr; 63(4):682-6; discussion 686-7. PubMed ID: 15072879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy for superficial bladder cancer.
    Baselli EC; Greenberg RE
    Oncology (Williston Park); 2001 Jan; 15(1):85-8; discussion 88-91. PubMed ID: 11271984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.
    Sylvester RJ
    Eur Urol; 2009 Aug; 56(2):266-8; discussion 268-9. PubMed ID: 19427110
    [No Abstract]   [Full Text] [Related]  

  • 6. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury.
    Chen F; Zhang G; Cao Y; Payne R; See WA
    J Urol; 2007 Nov; 178(5):2166-70. PubMed ID: 17870116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical mitomycin C for superficial transitional cell carcinoma.
    Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
    Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
    J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
    Dalbagni G
    Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109
    [No Abstract]   [Full Text] [Related]  

  • 11. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.
    Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP
    J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R; Kaasinen E; Sankila A; Rintala E;
    Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravesical chemotherapy and immunotherapy on semen analysis.
    Raviv G; Pinthus JH; Shefi S; Mor Y; Kaufman-Francis K; Levron J; Weissenberg R; Ramon J; Madgar I
    Urology; 2005 Apr; 65(4):765-7. PubMed ID: 15833524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
    Saint F
    Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).
    Oosterlinck W; Kirkali Z; Sylvester R; da Silva FC; Busch C; Algaba F; Collette S; Bono A
    Eur Urol; 2011 Mar; 59(3):438-46. PubMed ID: 21156335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
    Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S
    G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
    [No Abstract]   [Full Text] [Related]  

  • 18. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
    Di Stasi SM; Giannantoni A; Giurioli A; Valenti M; Zampa G; Storti L; Attisani F; De Carolis A; Capelli G; Vespasiani G; Stephen RL
    Lancet Oncol; 2006 Jan; 7(1):43-51. PubMed ID: 16389183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WITHDRAWN: Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T I bladder cancer.
    Shelley M; Court JB; Kynaston HG; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2015 Nov; (11):CD003231. PubMed ID: 26544085
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.